HK1215795A1 - 鵝膏毒素衍生物 - Google Patents

鵝膏毒素衍生物

Info

Publication number: HK1215795A1
Authority: HK; Hong Kong
Prior art keywords: amatoxin derivatives; amatoxin; derivatives
Prior art date: 2013-03-04

Application number

HK16103769.5A

Other languages

English (en)

Inventor

Christoph Mller

Jan Anderl

Werner Simon

Christian Lutz

Torsten Hechler

Original Assignee

Heidelberg Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-04

Filing date

2016-04-01

Publication date

2016-09-15

2016-04-01 Application filed by Heidelberg Pharma Gmbh filed Critical Heidelberg Pharma Gmbh

2016-09-15 Publication of HK1215795A1 publication Critical patent/HK1215795A1/zh

Links

WVHGJJRMKGDTEC-WCIJHFMNSA-N 2-[(1R,4S,8R,10S,13S,16S,27R,34S)-34-[(2S)-butan-2-yl]-8,22-dihydroxy-13-[(2R,3S)-3-hydroxybutan-2-yl]-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide Chemical class CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2 WVHGJJRMKGDTEC-WCIJHFMNSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Oncology (AREA)
Toxicology (AREA)
Mycology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Gastroenterology & Hepatology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

HK16103769.5A 2013-03-04 2016-04-01 鵝膏毒素衍生物 HK1215795A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP13001074.7A EP2774624A1 (en)	2013-03-04	2013-03-04	Amatoxin derivatives
PCT/EP2014/000614 WO2014135282A1 (en)	2013-03-04	2014-03-10	Amatoxin derivatives

Publications (1)

Publication Number	Publication Date
HK1215795A1 true HK1215795A1 (zh)	2016-09-15

Family

ID=47826817

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HK14113008.7A HK1200312A1 (zh)	2013-03-04	2014-12-24	毒傘肽衍生物
HK16103769.5A HK1215795A1 (zh)	2013-03-04	2016-04-01	鵝膏毒素衍生物

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
HK14113008.7A HK1200312A1 (zh)	2013-03-04	2014-12-24	毒傘肽衍生物

Country Status (20)

Country	Link
US (1)	US9982018B2 (zh)
EP (2)	EP2774624A1 (zh)
KR (1)	KR20160006162A (zh)
AR (1)	AR095019A1 (zh)
AU (1)	AU2014224928B2 (zh)
BR (1)	BR112015021838B1 (zh)
CA (1)	CA2903614C (zh)
DK (1)	DK2964264T3 (zh)
ES (1)	ES2652182T3 (zh)
HK (2)	HK1200312A1 (zh)
IL (1)	IL240863B (zh)
MX (1)	MX366503B (zh)
NO (1)	NO2964264T3 (zh)
NZ (1)	NZ710729A (zh)
RU (1)	RU2695370C2 (zh)
SG (1)	SG11201507089PA (zh)
TW (1)	TW201441248A (zh)
UA (1)	UA117364C2 (zh)
WO (1)	WO2014135282A1 (zh)
ZA (1)	ZA201505790B (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2015314826A1 (en)	2014-09-12	2017-03-02	Genentech, Inc.	Cysteine engineered antibodies and conjugates
SG11201701627PA (en)	2014-09-12	2017-03-30	Genentech Inc	Anti-cll-1 antibodies and immunoconjugates
AU2015314954B2 (en)	2014-09-12	2021-05-13	Genentech, Inc.	Anti-HER2 antibodies and immunoconjugates
US9938323B2 (en)	2014-11-06	2018-04-10	Novartis Ag	Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
SI3265565T1 (sl)	2015-03-04	2020-12-31	Board Of Regents, The University Of Texas System	Metode zdravljenje raka s hemizigotnimi izgubami TP53
PT3268047T (pt) *	2015-03-09	2023-12-05	Heidelberg Pharma Res Gmbh	Conjugados amatoxina-anticorpo
JP6632118B2 (ja) *	2015-09-04	2020-01-15	学校法人岩手医科大学	腫瘍の再発を抑制する医薬
MA43354A (fr)	2015-10-16	2018-08-22	Genentech Inc	Conjugués médicamenteux à pont disulfure encombré
WO2017191579A1 (en) *	2016-05-05	2017-11-09	Novartis Ag	Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
JP7022080B2 (ja)	2016-05-27	2022-02-17	ジェネンテック，インコーポレイテッド	部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
WO2017219025A1 (en)	2016-06-17	2017-12-21	Magenta Therapeutics, Inc.	Compositions and methods for the depletion of cells
IL303455A (en)	2016-06-17	2023-08-01	Crispr Therapeutics Ag	Compositions and methods for depleting CD117 plus cells
US11046776B2 (en)	2016-08-05	2021-06-29	Genentech, Inc.	Multivalent and multiepitopic antibodies having agonistic activity and methods of use
KR102455175B1 (ko)	2016-12-23	2022-10-17	하이델베르크 파마 리서치 게엠베하	아마니틴 접합체
TWI825007B (zh)	2017-01-20	2023-12-11	德商海德堡醫藥研究有限責任公司	用於cd137＋細胞耗盡（depletion）之組合物及方法
EP3738608A4 (en) *	2017-08-18	2021-12-08	Sichuan Baili Pharm Co. Ltd	NON-NATURAL AMATOXIN TYPE ANTIBODY CONJUGATE
AU2018337671B2 (en)	2017-09-19	2021-03-04	Paul Scherrer Institut	Transglutaminase conjugation method and linker
MX2020004140A (es)	2017-10-24	2020-08-13	Magenta Therapeutics Inc	Composiciones y metodos para la eliminacion de celulas cd117+.
TW201922782A (zh)	2017-10-24	2019-06-16	美商麥珍塔治療學股份有限公司	去除cd117+細胞之組合物及方法
US20210077571A1 (en) *	2018-04-13	2021-03-18	Heidelberg Pharma Research Gmbh	Targeted amatoxin conjugate for the treatment of solid tumors
CA3107383A1 (en)	2018-07-23	2020-01-30	Magenta Therapeutics, Inc.	Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
AU2020263959A1 (en)	2019-04-24	2021-11-25	Heidelberg Pharma Research Gmbh	Amatoxin antibody-drug conjugates and uses thereof
BR112021023226A2 (pt)	2019-05-23	2022-01-04	Heidelberg Pharma Res Gmbh	Composto, conjugado, método para sintetizar os conjugados e composição farmacêutica
KR102092817B1 (ko) *	2019-08-22	2020-03-24	한국화학연구원	아마톡신 유도체 및 이의 제조방법
CN111308100B (zh) *	2020-04-13	2023-04-21	北京维德维康生物技术有限公司	一种检测β-鹅膏毒肽的酶联免疫试剂盒及其制备和应用
CN116406302A (zh)	2020-09-18	2023-07-07	阿拉里斯生物技术股份公司	用基于氨基酸的接头的谷氨酰胺转胺酶缀合方法
KR20230096052A (ko)	2020-10-25	2023-06-29	아라리스 바이오테크 아게	항체-링커 접합체를 생성하기 위한 수단 및 방법
IL304966A (en) *	2021-03-19	2023-10-01	Heidelberg Pharma Res	B-lymphocyte specific Amatoxin conjugated antibodies
EP4422695A1 (en)	2021-10-25	2024-09-04	Araris Biotech AG	Methods for producing antibody-linker conjugates
CN118742328A (zh)	2022-02-22	2024-10-01	阿拉里斯生物技术股份公司	包含两个或更多个有效载荷的肽接头

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
EP2015782A4 (en) *	2006-04-12	2010-04-07	Crosslink Genetics Corp	COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
EP1859811B1 (en)	2006-05-27	2011-08-24	Faulstich, Heinz, Dr.	Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy
AU2010234335A1 (en)	2009-04-08	2011-10-13	Deutsches Krebsforschungszentrum	Amatoxin-armed target-binding moieties for the treatment of cancer
ES2784829T3 (es) *	2009-04-08	2020-10-01	Faulstich Heinz Dr	Componentes de unión a la superficie de células terapéuticas provistos de amatoxina diseñados para terapia de tumores
ES2402254T3 (es) *	2010-09-30	2013-04-30	Heidelberg Pharma Ag	Conjugados de amatoxinas con ligadores mejorados
EP2497499A1 (en) *	2011-03-10	2012-09-12	Heidelberg Pharma GmbH	Amatoxin-conjugates with improved linkages

2013
- 2013-03-04 EP EP13001074.7A patent/EP2774624A1/en not_active Withdrawn
2014
- 2014-03-04 TW TW103107305A patent/TW201441248A/zh unknown
- 2014-03-05 AR ARP140100717A patent/AR095019A1/es unknown
- 2014-03-10 DK DK14709884.2T patent/DK2964264T3/en active
- 2014-03-10 KR KR1020157027378A patent/KR20160006162A/ko not_active Application Discontinuation
- 2014-03-10 RU RU2015142093A patent/RU2695370C2/ru active
- 2014-03-10 EP EP14709884.2A patent/EP2964264B1/en active Active
- 2014-03-10 BR BR112015021838-5A patent/BR112015021838B1/pt active IP Right Grant
- 2014-03-10 AU AU2014224928A patent/AU2014224928B2/en active Active
- 2014-03-10 US US14/769,970 patent/US9982018B2/en active Active
- 2014-03-10 MX MX2015011583A patent/MX366503B/es active IP Right Grant
- 2014-03-10 NZ NZ710729A patent/NZ710729A/en unknown
- 2014-03-10 NO NO14709884A patent/NO2964264T3/no unknown
- 2014-03-10 SG SG11201507089PA patent/SG11201507089PA/en unknown
- 2014-03-10 CA CA2903614A patent/CA2903614C/en active Active
- 2014-03-10 ES ES14709884.2T patent/ES2652182T3/es active Active
- 2014-03-10 WO PCT/EP2014/000614 patent/WO2014135282A1/en active Application Filing
- 2014-10-03 UA UAA201509530A patent/UA117364C2/uk unknown
- 2014-12-24 HK HK14113008.7A patent/HK1200312A1/zh unknown
2015
- 2015-08-12 ZA ZA2015/05790A patent/ZA201505790B/en unknown
- 2015-08-26 IL IL240863A patent/IL240863B/en active IP Right Grant
2016
- 2016-04-01 HK HK16103769.5A patent/HK1215795A1/zh unknown

Also Published As

Publication number	Publication date
ZA201505790B (en)	2017-11-29
CA2903614C (en)	2021-07-06
UA117364C2 (uk)	2018-07-25
HK1200312A1 (zh)	2015-08-07
NO2964264T3 (zh)	2018-02-10
ES2652182T3 (es)	2018-01-31
TW201441248A (zh)	2014-11-01
MX2015011583A (es)	2016-07-29
DK2964264T3 (en)	2017-12-11
AU2014224928B2 (en)	2017-10-19
EP2964264B1 (en)	2017-09-13
WO2014135282A8 (en)	2015-09-17
US20160002298A1 (en)	2016-01-07
EP2774624A1 (en)	2014-09-10
EP2964264A1 (en)	2016-01-13
NZ710729A (en)	2019-05-31
BR112015021838A2 (pt)	2017-07-18
IL240863B (en)	2019-02-28
WO2014135282A1 (en)	2014-09-12
AU2014224928A1 (en)	2015-09-10
AR095019A1 (es)	2015-09-16
MX366503B (es)	2019-07-11
US9982018B2 (en)	2018-05-29
IL240863A0 (en)	2015-10-29
SG11201507089PA (en)	2015-10-29
RU2015142093A (ru)	2017-04-07
BR112015021838B1 (pt)	2021-12-28
RU2695370C2 (ru)	2019-07-23
KR20160006162A (ko)	2016-01-18
CA2903614A1 (en)	2014-09-12

Publication	Publication Date	Title
HK1215795A1 (zh)	2016-09-15	鵝膏毒素衍生物
SG11201506100XA (en)	2015-09-29	Pyridazinone-amides derivatives
ZA201601333B (en)	2019-12-18	Oxoquinazolinyl-butanamide derivatives
SG11201605189YA (en)	2016-07-28	Imidazopyrazinone derivatives
AU353575S (en)	2014-02-07	Stamphousing
HK1213566A1 (zh)	2016-07-08	新的四唑酮衍生物
EP3009444A4 (en)	2016-11-30	ALPHA-oxoacyl-Amino-caprolactam derivative
AU4899P (en)	2014-08-15	Herbie53 Iresine herbstii
AU353330S (en)	2014-01-21	Kettlebell
AU353331S (en)	2014-01-21	Kettlebell
AU353325S (en)	2014-01-21	Kettlebell
AU353329S (en)	2014-01-21	Kettlebell
AU353326S (en)	2014-01-21	Kettlebell
AU353328S (en)	2014-01-21	Kettlebell
AU2013231V (en)	2014-06-11	Bonsca7200 Scaevola aemula
AU353341S (en)	2014-01-21	Playsuit
AU354283S (en)	2014-03-13	Playsuit
AP2013000704S (en)	2016-10-11	Gramoquat
AP2013000703S (en)	2016-10-11	Adwura wura
GB201311071D0 (en)	2013-08-07	Autodefrost
AP2013000598S (en)	2013-04-23	Nestank
AP2013000597S (en)	2013-04-23	Blueflame bioslurrigaz
AP2013000605S (en)	2013-05-09	Aquatank
AP2013000596S (en)	2013-04-23	Kentank
AP2013000606S (en)	2013-05-09	Loftank